High-Intensity Focused Ultrasound (HIFU) for Prostate Cancer
High-Intensity Focused Ultrasound (HIFU) is a prostate cancer treatment that uses focused ultrasound energy to destroy targeted tissue without surgical incisions or ionizing radiation. For men exploring alternatives to radical prostatectomy or radiation therapy, HIFU is often considered as a minimally invasive option.
However, while HIFU represents a step toward treating prostate cancer while preserving function and quality of life, it is not without potential side effects and risks.
Below, we explain how HIFU works, who may be a suitable candidate, what the treatment process involves, and how it compares with other prostate cancer treatments.
Key Points
- High-Intensity Focused Ultrasound (HIFU) is a non-invasive treatment for prostate cancer that uses focused ultrasound energy to heat and destroy targeted tissue.
- It is most commonly used in patients with localized prostate cancer, especially when the tumour is confined to a well-defined area of the prostate.
- While HIFU is often performed as focal therapy, it remains a thermal treatment and may affect surrounding structures. Risks of urinary and sexual problems depend on treatment location.
- Non-thermal focal therapies offer an alternative to other treatments by treating cancer without heat or radiation. Their goal is to preserve surrounding structures and support immune response.
What Is High-Intensity Focused Ultrasound (HIFU)?
High-Intensity Focused Ultrasound (HIFU) is a non-invasive treatment that uses focused ultrasound energy to destroy cancer cells by heating targeted tissue. Rather than treating the entire gland, HIFU is most often performed as a focal therapy, targeting only selected areas.
The treatment works by concentrating multiple ultrasound beams on a precise location. Where these beams converge, energy builds and tissue temperature rises, while surrounding tissue along the beam path remains largely unaffected.
To support this level of targeting, treatment is planned and delivered using imaging guidance, most commonly ultrasound-based imaging, to define the treatment area.
Despite this precision, HIFU remains a thermal treatment. As with all heat-based approaches, there is a risk of unintended heating of nearby structures, which can result in urinary or sexual side effects depending on treatment location and extent.
HIFU Eligibility and Patient Selection
HIFU is generally considered for men with low- to intermediate-risk prostate cancer, particularly when the tumour is confined to a single, well-defined area. It is less suitable for aggressive, high-risk, or more widespread disease involving multiple regions.
Most candidates have Gleason scores of 6 or 7, with tumours that are visible on MRI prior to treatment.
Although HIFU technology has been approved by the FDA for the treatment of prostate tissue, it is not widely recommended as a first-line treatment by most expert groups. For some men, however, it may be considered when the goal is to avoid surgery or radiation and active surveillance is not preferred.
The HIFU Treatment Process
The HIFU treatment process involves pre-treatment planning, targeted ultrasound ablation, and a short recovery period with scheduled follow-up. While details may vary slightly between centres, this reflects the general approach most practitioners follow.
The HIFU procedure starts with a pre-treatment assessment, typically conducted a few weeks before treatment. At this stage, patients are evaluated for general health, current medications, and suitability for general anesthesia.
This is also when ultrasound-based scanning is completed to create a three-dimensional treatment model, which is used to define the targeted ablation area.
On the day of treatment, patients are given an enema to clear the rectum. Once the enema has taken effect, patients are placed under general anesthesia, followed by insertion of a urinary catheter.
With preparation complete, an ultrasound probe is placed into the rectum to deliver focused ultrasound energy to the prostate. High-intensity focused ultrasound waves heat the targeted prostate tissue to approximately 70°C–90°C (158°F–194°F), causing cell destruction.
The entire procedure typically takes between one and four hours to complete.
As a minimally invasive treatment, most HIFU patients can return home the same day, and many resume normal daily activities shortly afterward.
The urinary catheter is typically kept in place to reduce the risk of urinary retention caused by temporary swelling. A follow-up appointment is required to remove the catheter after several days to weeks.
Following treatment, PSA blood tests are commonly recommended at 3, 6, and 12 months to monitor treatment response.
Potential Benefits of HIFU for Prostate Cancer Treatment
HIFU is often considered by patients seeking a minimally invasive treatment that aims to balance cancer control with quality-of-life preservation. While outcomes depend on individual disease characteristics and treatment planning, several potential benefits have been associated with this approach.
- Minimally invasive approach: HIFU does not involve surgical incisions or ionizing radiation, which may reduce treatment-related trauma to surrounding tissues.
- Shorter recovery time: Many patients can return to normal daily activities relatively soon after treatment.
- Treatment flexibility: HIFU can be repeated in some cases if prostate cancer recurs within the treated area, depending on anatomy and prior treatment effects.
- Local cancer control: Many patients achieve disease control within the targeted treatment zone after HIFU, although additional treatment may be required if cancer is detected outside the treated area.
- Potential preservation of function: By limiting treatment to selected areas of the prostate, HIFU may help preserve urinary continence and sexual function compared with surgery or radiation therapy.
HIFU Prostate Cancer Side Effects, Risks, and Limitations
While HIFU is generally well tolerated and designed to reduce side effects compared with more aggressive treatments, it remains a thermal therapy and carries important risks and limitations that should be considered.
- Temporary urinary difficulties: Prostate swelling after treatment may cause urgency, frequency, or difficulty urinating during recovery. Short-term catheterization is commonly required to allow swelling to subside.
- Bleeding-related symptoms: Blood may be noticed in the urine, semen, or rectum during early recovery and is typically self-limiting.
- Urinary and sexual side effects: Urinary incontinence and erectile dysfunction can occur, with risk and severity influenced by treatment location, extent of ablation, and individual anatomy.
- Other potential complications: Less common risks include urinary retention, infection, ejaculatory changes, urethral stricture, and, rarely, rectal injury.
- Thermal treatment limitations: As a heat-based therapy, HIFU carries a risk of unintended damage to surrounding healthy tissue, particularly near nerves, blood vessels, and the urethra.
- Limited long-term durability data: Long-term cancer control data for HIFU are less established than for surgery or radiation, and additional treatment may be required if cancer recurs.
How HIFU Compares to Other Prostate Cancer Treatments
HIFU is one of several minimally invasive treatment options for prostate cancer. Below, we compare HIFU with other commonly used therapies to highlight key differences in treatment delivery, precision, and limitations.
Alternative Prostate Cancer Treatments →
HIFU vs Cryotherapy
Both HIFU and cryotherapy are focal treatments that rely on thermal energy to destroy prostate tissue. However, while HIFU destroys cancer cells using heat, cryotherapy works by freezing the affected area.
The two treatments also differ in how energy is delivered. HIFU delivers ultrasound energy through a single probe, whereas cryotherapy typically requires multiple probes placed directly into the prostate.
Both treatments can be repeated if cancer recurs, depending on the anatomy and prior treatment effects. However, cryotherapy may be associated with a higher risk of nerve injury and complications related to ice spread beyond the intended treatment zone, particularly in specific anatomical locations.
HIFU vs TULSA Pro
Both HIFU and TULSA Pro use ultrasound energy to destroy prostate tissue through heat. However, the two treatments differ in how that energy is delivered and how the treatment is guided.
HIFU delivers ultrasound energy via a transrectal approach, while TULSA Pro uses a transurethral applicator positioned within the urethra. TULSA Pro relies on real-time MRI guidance during treatment, whereas HIFU typically uses ultrasound-based imaging for treatment planning and delivery.
Because of these differences, TULSA Pro is more often used for whole-gland ablation in clinical practice, while HIFU is most commonly performed as a focal treatment targeting selected areas of the prostate gland. However, the transurethral approach used in TULSA Pro may limit access to specific tumour locations depending on prostate anatomy.
Both treatments aim to reduce side effects compared with surgery or radiation therapy. Still, as thermal therapies, they share similar limitations when treating areas near sensitive structures, such as nerves, blood vessels, and the urethra.
HIFU vs CyberKnife
HIFU and CyberKnife differ fundamentally in how prostate tissue is treated. HIFU uses focused ultrasound energy to destroy prostate tissue through heat, while CyberKnife delivers high-dose radiation to target cancer cells.
HIFU is most often used as a focal therapy, treating selected areas of the prostate, whereas CyberKnife typically targets a larger treatment volume. Unlike CyberKnife, HIFU does not involve ionizing radiation, which may reduce the risk of radiation-related exposure to surrounding tissues.
Treatment delivery also differs between the two approaches. HIFU is usually performed as a single procedure, while CyberKnife treatment is delivered over multiple sessions. Radiation-related side effects may develop months or years after CyberKnife treatment, whereas HIFU-related side effects tend to occur earlier during the recovery period.
CyberKnife is commonly used across a broader range of prostate cancer risk levels, including some higher-risk cases. In contrast, HIFU is used mainly for localized, low- to intermediate-risk prostate cancer.
Non-Thermal Alternatives to HIFU for Prostate Cancer
Unlike thermal-based minimally invasive prostate cancer treatments, electroporation-based therapies aim to destroy cancer cells without the use of heat, radiation, or surgery. By avoiding thermal injury, these approaches are designed to reduce damage to surrounding tissues and help preserve function and quality of life in selected prostate cancer patients.
Minimally Invasive Prostate Cancer Therapies →
Irreversible Electroporation (IRE)
Irreversible Electroporation (IRE) uses short electrical pulses to destroy cancer cells without heat. Using NanoKnife® technology, this non-thermal ablation approach helps minimize collateral damage to surrounding tissue, including blood vessels and nerves.
As a result, IRE has been associated with lower rates of urinary and sexual side effects compared with surgery, radiation therapy, and thermal focal treatments. At VITUS Private Clinic, clinical experience across more than 2,000 treated patients has demonstrated a 90–95% potency retention rate and 100% continence preservation.
In addition to a gentler treatment profile, IRE offers broader eligibility than HIFU. It may be used for localized prostate cancer, intermediate-risk disease, and selected advanced or recurrent cases, including metastatic recurrences.
Electrochemotherapy
Electrochemotherapy for prostate cancer is another specialized treatment option offered at VITUS Private Clinic. This approach combines short electrical pulses with targeted chemotherapy delivery, temporarily opening cancer cell membranes to enhance the chemotherapeutic agent’s uptake.
Because the drug is delivered directly to the tumour, substantially lower chemotherapy doses are required. This helps reduce the systemic side effects and toxicity typically associated with conventional chemotherapy.
In selected cases, electrochemotherapy may be combined with irreversible electroporation (IRECT) to treat advanced or recurrent prostate cancer, including disease involving sensitive surrounding structures such as the sphincter, rectum, or bladder wall.
Immunotherapy
The immune system plays a critical role in identifying and controlling prostate cancer cells that extend beyond the prostate. Immunotherapy for prostate cancer aims to support this process by enhancing the immune system’s ability to recognize and respond to cancer cells.
One challenge is that prostate cancer is often considered immunologically “cold,” meaning tumour cells may not be easily recognized by the immune system. For immunotherapy to be effective, cancer cells must first be made visible to the immune system through the release of prostate-specific antigens.
Thermal treatment methods, such as HIFU or cryotherapy, rely on extreme heat or cold to destroy tissue, which can damage or denature these tumour antigens. In contrast, non-thermal treatments such as irreversible electroporation (IRE), electrochemotherapy (ECT), and IRECT are able to destroy cancer cells without heat, allowing prostate-specific antigens to remain intact and be released.
Exploring Non-Thermal Treatment Options at Vitus
At VITUS Private Clinic, we specialize in non-thermal, minimally invasive treatment approaches designed to preserve surrounding structures and reduce treatment-related side effects.
If you are exploring alternatives to surgery, radiation, or thermal focal therapies such as HIFU, our team can help you assess whether options like irreversible electroporation, electrochemotherapy, or immunotherapy-supported approaches may be appropriate for your individual case.
Contact the team at Vitus Private Clinic to request a case review and discuss which treatment options may be appropriate.
FAQ
HIFU is used to treat localized or early-stage prostate cancer in selected patients. It is most often applied as a focal therapy, targeting a specific tumour area rather than treating the whole prostate. It is generally considered for men with low- to intermediate-risk disease.
HIFU may be appropriate for men with localized prostate cancer where the tumour is confined to a well-defined area and visible on imaging tests. Candidates typically have favourable biopsy results, lower PSA levels, and disease that does not require whole-prostate treatment.
HIFU uses a special ultrasound probe to deliver focused ultrasound energy to targeted tissue within the prostate. The procedure is performed under general anesthesia using real-time imaging to raise tissue temperatures and destroy cancer cells while limiting exposure to surrounding structures.
Most side effects after HIFU are temporary and relate to urinary and sexual function. Common issues include short-term urinary problems such as urgency or slower flow, as well as possible erection problems. The risk and severity depend on treatment location and extent.
If HIFU is not appropriate, non-thermal focal therapies such as Irreversible Electroporation (IRE) or Electrochemotherapy offer a minimally invasive alternative to surgery and radiation, with broader eligibility and greater ability to preserve urinary and sexual function.